Genetic Analysis: Q2 2025 delivered strong sales growth, positive EBITDA, and strategic expansion in key markets

About this update from Genetic Analysis As

Q2 2025 saw 34% sales growth year-over-year, a positive EBITDA, and a narrowed net loss, driven by strong US sales and new product launches. Capital raises strengthened the balance sheet, while new partnerships and product launches in China and the US support future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genetic Analysis As